Modality
Degrader
MOA
FXIai
Target
VEGF
Pathway
DDR
Breast CaCholangiocarcinomaRSV
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Jun 2028
Phase 2Current
NCT07235590
2,036 pts·Cholangiocarcinoma
2017-04→2028-06·Terminated
2,036 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-232mo awayAdCom· Cholangiocarcinoma
2028-06-142.2y awayPh2 Data· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Termina…
Catalysts
AdCom
2026-05-23 · 2mo away
Cholangiocarcinoma
Ph2 Data
2028-06-14 · 2.2y away
Cholangiocarcinoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07235590 | Phase 2 | Cholangiocarcinoma | Terminated | 2036 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |